Yahoo · Sep 17, 2026
RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.
AM
NASDAQ · AMRN
Amarin Corporation plc
Healthcare · Biotechnology
$12.09
Down-$0.02 (-0.17%)
Updated Oct 6, 2026, 10:38 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 285.42M
- P/E ratio
- -147.97
- Dividend yield
- 0.00%
- 52-week range
- $12.00 – $17.25
- Volume
- 79.84K
- Avg. volume
- 93.27K
Price performance · AMRN
AMRN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
AMRN closed at $12.09 after 20 trading sessions, down 15.16% for the selected period.
- Last close
- $12.09
- Period change
- -15.16%
- Period low
- $12.09
- Period high
- $14.39
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $12.29 | $12.335 | $12.00 | $12.09 | 79.84K |
| Oct 2, 2026 | $13.00 | $13.02 | $12.31 | $12.35 | 100.39K |
| Oct 1, 2026 | $13.00 | $13.035 | $12.63 | $12.72 | 77.33K |
| Sep 30, 2026 | $13.01 | $13.23 | $12.98 | $13.00 | 62.54K |
| Sep 29, 2026 | $13.24 | $13.28 | $13.04 | $13.14 | 19.82K |
| Sep 28, 2026 | $13.19 | $13.47 | $13.0584 | $13.25 | 22.79K |
| Sep 25, 2026 | $13.40 | $13.40 | $13.00 | $13.20 | 127.28K |
| Sep 24, 2026 | $13.58 | $13.63 | $13.40 | $13.43 | 47.94K |
| Sep 23, 2026 | $13.71 | $13.8053 | $13.4988 | $13.72 | 59.84K |
| Sep 22, 2026 | $13.515 | $13.90 | $13.515 | $13.75 | 59.06K |
| Sep 21, 2026 | $13.63 | $13.80 | $13.375 | $13.48 | 38.79K |
| Sep 18, 2026 | $13.84 | $13.90 | $13.58 | $13.63 | 50.66K |
| Sep 17, 2026 | $13.92 | $13.95 | $13.72 | $13.87 | 24.34K |
| Sep 16, 2026 | $13.97 | $14.08 | $13.78 | $13.84 | 45.09K |
| Sep 15, 2026 | $13.95 | $13.97 | $13.72 | $13.93 | 41.11K |
| Sep 14, 2026 | $13.76 | $14.08 | $13.76 | $14.00 | 38.27K |
| Sep 11, 2026 | $14.09 | $14.10 | $13.68 | $13.80 | 49.37K |
| Sep 10, 2026 | $14.27 | $14.298 | $13.895 | $14.04 | 51.75K |
| Sep 9, 2026 | $14.17 | $14.395 | $14.07 | $14.39 | 33.69K |
| Sep 8, 2026 | $13.52 | $14.30 | $13.19 | $14.25 | 99.81K |
Latest AMRN news
The latest Smart Investors Daily articles mentioning AMRN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AMRN research
Overview
Company profile and research snapshot.
Company profile
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.17
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 21, 2026 | JP Morgan | Underweight | — |
| Jun 25, 2025 | Goldman Sachs | Sell | — |
| Apr 17, 2025 | Goldman Sachs | Sell | — |
| Jun 20, 2024 | Cantor Fitzgerald | Overweight | — |
| Jun 18, 2024 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 10, 2026
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Aug 31, 2026
Amarin Highlights New REDUCE-IT® and Mechanistic Data Presented at European Society of Cardiology (ESC) Congress 2026
Presentations Expand Understanding of Treatment Adherence, Long-Term Outcomes, Lipoprotein(a), Coagulation Biomarkers, and Potential Mechanisms of Eicosapentaenoic Acid (EPA) 2026 ESC/European Renal Association (ERA) Cardiovascular and Chronic Kidney Disease Guideline Further Reinforces the Clinical Evidence Supporting Icosapent Ethyl DUBLIN and BRIDGEWATER, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascula
Yahoo · Aug 28, 2026
New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients
Data Supports Approximately 30% Relative Risk Reduction Among Highly Adherent Patients and Provides Evidence Consistent with a Potential Legacy Effect in Secondary Prevention Patients After Treatment DiscontinuationDUBLIN and BRIDGEWATER, N.J., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today highlighted a new post hoc analysis from the landmark REDUCE-IT® cardiovascular outcomes trial,
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
